ClinicalTrials.gg
CompletedNCT00988533Updated Apr 25, 2012Results posted

A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age

A Phase 1 interventional study of 0.5% Ivermectin Cream in Head Lice, sponsored by Topaz Pharmaceuticals Inc. Completed at 5 sites in United States. Open to participants aged 6 Months to 3 Years. Per ClinicalTrials.gov, last updated 2012-04-25.

Sponsored by Topaz Pharmaceuticals Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Months to 3 Years
Sex
All
01

Study summary

The purpose of this study is to determine the bioavailability of 0.5% ivermectin cream in a pediatric population aged 6 months to 3 years.

02

Conditions studied

  • Head Lice

Keywords

  • Head Lice
  • Pediculus
03

In context

Lead sponsor

Topaz Pharmaceuticals Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 6 months to 3 years of age, inclusive, when is signed.
  • Subject must be infested with head lice as demonstrated by the presence of at least 1 live louse prior to treatment.
  • Subject is in general good health.
  • Subject's parent/guardian (caregiver) must be willing and able to bring subject to all study visits as scheduled.
  • Subject's caregiver must have provided written informed consent (assent is not required due to the young age of the subjects).
  • Subject's caregiver must agree to comply with the following study restrictions:

    • will not use any other form of lice treatment (eg, commercial, community/anecdotal, or mechanical/manual) on the subject for the duration of the study, unless directed to do so by study personnel.
    • will not shampoo, wash, or rinse the subject's hair or scalp until the Day 2 treatment evaluation has been completed.
    • will not cut or chemically treat subject's hair in the period between screening and follow-up on Day 15.
    • will use only study-provided shampoo on the subject for the duration of the study.
    • will follow all study instructions.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any OTC or prescription treatment for head lice in the last 2 weeks.
  • Subjects or subjects' caregivers who are unable to comply with the study obligations and all study visits.
  • Subjects whose caregivers do not understand the requirements for participation and/or may be likely to exhibit poor compliance, in the opinion of the Investigator.
  • Subjects with eczema, atopic dermatitis, or other chronic conditions of the scalp and skin.
  • Subjects with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is > 2, blisters, or any other condition that, in the opinion of the investigative personnel or Sponsor, would interfere with the PK, safety and/or efficacy evaluations.
  • Subjects with a history of allergy to ivermectin or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.
  • Subjects with other diagnoses that, in the opinion of the Investigator, would interfere with the PK, safety, and/or efficacy assessments or would preclude study participation.
  • Subjects who have been treated with a systemic antibiotic within 2 weeks before screening.
  • Subject currently taking warfarin sodium (Coumadin®) or has taken within 2 weeks before screening.
  • Subjects who have been enrolled in any clinical study within the past 30 days; subjects may not participate in another study while participating in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    0.5% Ivermectin Cream

    Drug: 0.5% Ivermectin Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points

    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods with a sensitivity of 0.05 ng/mL before application and on Day 1 (0.5, 1, and 6 hours), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

    Time frame: Before; 0.5, 1, 6, 24 hours and Up to 14 days post-application

  2. Summary of Pharmacokinetic Parameters Following Ivermectin Application.

    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

    Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application

  3. Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.

    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

    Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application

  4. Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.

    Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

    Time frame: Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application

Secondary outcomes

  1. Number of Participants Reporting Adverse Events Following Ivermectin Treatment

    Adverse events were assessed at each visit and during the follow up phone call on Day 28.

    Time frame: Day 1 up Day 28 post-application

  2. Percentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin.

    Eradication of live lice was assessed by visual examination of the scalp and hair.

    Time frame: Day 2, Day 8 and Day 15 post-application

  3. Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin.

    Eradication of live lice was assessed by visual examination of the scalp and hair before and following application of Ivermectin.

    Time frame: Day 2, Day 8 and Day 15 post-application

  4. Liver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application

    Liver function tests (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase) were performed before Ivermectin application on Day 1 (baseline) and on Days 2, 8, and 15 after application.

    Time frame: Day 1, Day 2, Day 8 and Day 15 post-application

  5. Liver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application

    Liver function test (total bilirubin) was performed before treatment Day 1 (baseline) and following Ivermectin application on Days 2, 8, and 15 Post-application, respectively.

    Time frame: Day 1, Day 2, Day 8 and Day 15 post-application

07

Results

Posted Apr 25, 2012

Participant flow

Participants were enrolled and treated from 22 September 2009 to 18 November 2009 at 3 US clinical centers.

Participant flow — Overall Study
Milestone0.5% Ivermectin
Started30
Completed27
Not completed3
Withdrew: Lost to follow-up3

Outcome measures

PrimaryMean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points

Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods with a sensitivity of 0.05 ng/mL before application and on Day 1 (0.5, 1, and 6 hours), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

Time frame:
Before; 0.5, 1, 6, 24 hours and Up to 14 days post-application
Reported as:
Mean · ng/mL
Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points
ng/mL0.5% Ivermectin
0 Hour (N = 20)0.00000 ± 0.00000
0.5 Hour (N = 19)0.02528 ± 0.11018
1 Hour (N = 19)0.08192 ± 0.22695
6 Hours (N = 19)0.20075 ± 0.20456
24 Hours (N = 18)0.16325 ± 0.08983
168 Hours (N = 2)0.05767 ± NA
PrimarySummary of Pharmacokinetic Parameters Following Ivermectin Application.

Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

Time frame:
Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Reported as:
Mean · ng/h/mL
Summary of Pharmacokinetic Parameters Following Ivermectin Application.
ng/h/mL0.5% Ivermectin
Time Averaged Plasma Concentration0.08708 ± 0.11102
Area Under Plasma Concentration Last6.701 ± 11.23
Area Under Plasma Concentration 0 to 243.972 ± 3.5142
SecondaryNumber of Participants Reporting Adverse Events Following Ivermectin Treatment

Adverse events were assessed at each visit and during the follow up phone call on Day 28.

Time frame:
Day 1 up Day 28 post-application
Reported as:
Number · Participants
Number of Participants Reporting Adverse Events Following Ivermectin Treatment
Participants0.5% Ivermectin
Diarrhea1
Severe Diarrhea0
Vomiting1
Severe Vomiting0
Gastroenteritis1
Severe Gastroenteritis0
Nasopharyngitis2
Severe Nasopharyngitis0
Upper Respiratory Tract Infection2
Severe Upper Respiratory Tract Infection0
Alanine Aminotransferase Increased2
Severe Alanine Aminotransferase Increased0
Aspartate Aminotransferase Increased1
Severe Aspartate Aminotransferase Increased0
Dehydration1
Severe Dehydration0
Dermatitis Diaper1
Severe Dermatitis Diaper0
Erythema5
Severe Erythema0
Pruritus1
Severe Pruritus0
SecondaryPercentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin.

Eradication of live lice was assessed by visual examination of the scalp and hair.

Time frame:
Day 2, Day 8 and Day 15 post-application
Reported as:
Number · Percent of Participants
Percentage of Participants Who Were Lice-Free by Visit Post-treatment With Ivermectin.
Percent of Participants0.5% Ivermectin
Day 2 (N = 30)97
Day 8 (N = 29)90
Day 15 (N = 28)89
SecondaryPercentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin.

Eradication of live lice was assessed by visual examination of the scalp and hair before and following application of Ivermectin.

Time frame:
Day 2, Day 8 and Day 15 post-application
Reported as:
Number · Percent of Participants
Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 8 and Day 15 Post-treatment With Ivermectin.
Percent of Participants0.5% Ivermectin
Eradication by Day 2 (N = 30)97
Eradication Maintained Through Day 8 and 15 (N=29)86
SecondaryLiver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application

Liver function tests (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase) were performed before Ivermectin application on Day 1 (baseline) and on Days 2, 8, and 15 after application.

Time frame:
Day 1, Day 2, Day 8 and Day 15 post-application
Reported as:
Mean · U/L
Liver Function Test Results at Before (Day 1) and Following Ivermectin Application on Days 2, 8, and 15 Post-application
U/L0.5% Ivermectin
Alkaline Phosphatase - Day 1257.9 ± 59.5
Alkaline Phosphatase Day 2258.0 ± 58.4
Alkaline Phosphatase Change from Day 1 to 24.2 ± 16.5
Alkaline Phosphatase Day 8259.1 ± 51.0
Alkaline Phosphatase Change from Day 1 to 8-2.2 ± 28.4
Alkaline Phosphatase Day 15258.3 ± 52.6
Alkaline Phosphatase Change from Day 1 to 15-2.9 ± 32.3
Alanine Aminotransferase Day 125.0 ± 20.5
Alanine Aminotransferase Day 225.7 ± 20.9
Alanine Aminotransferase Change from Day 1 to 20.2 ± 20.9
Alanine Aminotransferase Day 825.1 ± 22.1
Alanine Aminotransferase Change from Day 1 to 8-0.2 ± 5.3
Alanine Aminotransferase Day 1524.1 ± 15.5
Alanine Aminotransferase Change from Day 1 to 15-1.1 ± 8.9
Aspartate Aminotransferase Day 142.6 ± 15.4
Aspartate Aminotransferase Day 241.1 ± 11.5
Aspartate Aminotransferase Change from Day 1 to 2-2.0 ± 15.4
Aspartate Aminotransferase Day 840.3 ± 14.0
Aspartate Aminotransferase Change from Day 1 to 8-2.3 ± 6.8
Aspartate Aminotransferase Day 1539.5 ± 9.6
Aspartate Aminotransferase Change from Day 1 to 15-2.7 ± 10.2
Lactate Dehydrogenase Day 1308.0 ± 87.5
Lactate Dehydrogenase Change Day 2295.2 ± 35.8
Lactate Dehydrogenase Change from Day 1 to 2-16.8 ± 95.1
Lactate Dehydrogenase Day 8295.1 ± 54.0
Lactate Dehydrogenase Change from Day 1 to 8-10.7 ± 80.2
Lactate Dehydrogenase 15294.5 ± 61.3
Lactate Dehydrogenase Change from Day 1 to 15-9.2 ± 69.0
SecondaryLiver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application

Liver function test (total bilirubin) was performed before treatment Day 1 (baseline) and following Ivermectin application on Days 2, 8, and 15 Post-application, respectively.

Time frame:
Day 1, Day 2, Day 8 and Day 15 post-application
Reported as:
Mean · mg/dL
Liver Function Test Results at Before (Baseline) and Following Ivermectin Application on Days 2, 8, and 15 Post-application
mg/dL0.5% Ivermectin
Total Bilirubin - Day 10.3 ± 0.3
Total Bilirubin Day 20.3 ± 0.3
Total Bilirubin Change from Day 1 to 2-0.0 ± 0.1
Total Bilirubin Day 80.3 ± 0.3
Total Bilirubin Change from Day 1 to 8-0.0 ± 0.1
Total Bilirubin Day 150.3 ± 0.3
Total Bilirubin Change from Day 1 to 15-0.1 ± 0.2
PrimarySummary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.

Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

Time frame:
Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Reported as:
Mean · ng/mL
Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.
ng/mL0.5% Ivermectin
Summary of Pharmacokinetic Parameter (Mean Concentration) Following Ivermectin Application.0.241 ± 0.23372
PrimarySummary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.

Plasma concentrations of ivermectin were measured by validated and appropriate bioanalytical instruments and methods before application and on Day 1 (0.5, 1, and 6 hours post-application), Day 2 (24 hours post-application), Day 8 (7 days post-application), and Day 15 (14 days post-application).

Time frame:
Before; 0.5, 1, 6, 24 hours, Day 8 and Day 15 post-application
Reported as:
Mean · hour
Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.
hour0.5% Ivermectin
Summary of Pharmacokinetic Parameter (Time of Observed Maximum Plasma Concentration) Following Ivermectin Application.15.9 ± 10

Adverse events

Collected over Adverse event data were collected from the day of application (Day 1) through Day 28 post-application. Non-serious events are listed at a 5.00% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5% Ivermectin—1/30 (3.3%)11/30 (36.7%)
Most frequent serious events
Most frequent serious events
Event0.5% Ivermectin
GastroenteritisInfections and infestations1/30
DehydrationMetabolism and nutrition disorders1/30
Dermatitis DiaperSkin and subcutaneous tissue disorders1/30
Most frequent other events
Most frequent other events
Event0.5% Ivermectin
ErythemaSkin and subcutaneous tissue disorders5/30
NasopharyngitisInfections and infestations2/30
Upper Respiratory Tract InfectionInfections and infestations2/30
Alanine Aminotransferase IncreasedInvestigations2/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)0.5% Ivermectin
<=18 years30
Between 18 and 65 years0
>=65 years0
Age Continuous
Age Continuous(Months)0.5% Ivermectin
Mean25.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)0.5% Ivermectin
Female23
Male7
Region of Enrollment
Region of Enrollment(Participants)0.5% Ivermectin
United States30
08

Study locations

5 sites
  • Children's Investigational Research Program
    Bentonville, Arkansas 72712, United States
  • Universal BioPharma Research, Inc
    Dinuba, California 93618, United States
  • Impact Clinical Trials
    Los Angeles, California 90036, United States
  • Lice Source Solutions Inc
    Plantation, Florida 33313, United States
  • Spence Medical Research L.L.C
    Picayune, Mississippi 39466, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2009
First posted
Oct 2, 2009
Start
Sep 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Apr 25, 2012
Last update
Apr 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00988533
Lead sponsor
Topaz Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Oct 2, 2009
Start date
Sep 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Apr 25, 2012
Last update
Apr 25, 2012

Study contacts

Medical Director
study director · Sanofi Topaz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion